Nasus Pharma to present at investor conferences in May, highlighting its innovative intranasal drug development.

Nasus Pharma, a clinical-stage pharmaceutical company specializing in intranasal drug products, announced its management will attend two investor conferences in New York on May 5 and May 7, 2026. CFO Eyal Rubin will hold one-on-one meetings to discuss the company's progress, including its lead product NS002, an intranasal epinephrine powder designed as a needle-free alternative for anaphylaxis treatment. This participation aims to engage investors ahead of pivotal clinical studies, emphasizing the potential of their proprietary powder-based intranasal technology for rapid drug delivery. Investors interested in meetings are advised to contact their representatives at sponsoring institutions.